Business Context and Reporting Period
This Form 8-K, dated August 7, 2025, reports on the reconvened special meeting of stockholders for ReShape Lifesciences Inc. (RSLS). The meeting addressed matters previously adjourned on July 24, 2025, specifically regarding a proposed asset sale and a merger with Vyome Therapeutics, Inc.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance actions and voting results.
Material Changes and Voting Results
Stockholders approved two critical proposals at the reconvened meeting:
- Proposal 2 (Asset Sale): Approval of the sale of substantially all company assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd.
- Votes For: 1,273,715
- Votes Against: 26,206
- Abstentions: 2,305
- Proposal 3 (Merger Amendments): Approval of amendments to the Restated Certificate of Incorporation to facilitate the merger with Vyome Therapeutics, Inc.
- Votes For: 1,240,191
- Votes Against: 58,555
- Abstentions: 3,480
Outlook, Risks, and Management Commentary
The filing indicates that the approved amendments to the Certificate of Incorporation will take effect substantially concurrently with the effective time of the Merger. No specific guidance, risk factors, or management commentary regarding future financial performance is included in this specific report.
Key Facts for Investor Verification
- Verify the closing conditions and timeline for the asset sale to Ninjour Health International Limited.
- Confirm the effective date of the merger with Vyome Therapeutics, Inc.
- Review the full Proxy Statement (filed June 24, 2025) for detailed terms of the asset sale and merger.
- Monitor subsequent filings for the impact of these transactions on the company's capital structure and operations.